Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Royalty Pharma (NASDAQ: RPRX) and raised the price target from $65 to $67. This adjustment reflects a positive outlook for the company's stock performance.